KalVista Pharmaceuticals, Inc. (KALV) Announces Q3 Loss While Exceeding Revenue Projections
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy KALV?
Source: NASDAQ.COM
Quarterly Performance: KalVista Pharmaceuticals reported a quarterly loss of $0.92 per share, slightly better than the expected loss of $0.96, with revenues of $13.69 million, significantly surpassing estimates by 242.30%.
Stock Outlook: The company's stock has increased by 27.3% since the start of the year, outperforming the S&P 500, but future performance will depend on management's commentary and earnings estimate revisions.
Earnings Estimates: Current consensus estimates for the next quarter are a loss of $0.85 per share on $12.8 million in revenues, while the fiscal year estimate is a loss of $2.94 on $16.9 million in revenues.
Industry Context: KalVista operates in the Medical - Drugs industry, which ranks in the top 37% of Zacks industries, indicating a favorable environment that could influence stock performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KALV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KALV
Wall Street analysts forecast KALV stock price to rise
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 19.330
Low
29.00
Averages
34.38
High
39.00
Current: 19.330
Low
29.00
Averages
34.38
High
39.00
About KALV
KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drug therapies for diseases with significant unmet need. Its product candidate is sebetralstat, an inhibitor of plasma kallikrein being developed for hereditary angioedema (HAE). Sebetralstat is designed to offer people living with HAE a medication that can be taken as a discreet oral dose to readily treat HAE attacks on-demand, including at the earliest signs before the attack fully develops. Sebetralstat works by targeting the kallikrein-kinin system (KKS) cascade, selectively inhibiting plasma kallikrein and its uncontrolled activity that drives HAE attacks. The Company is also designing an oral Factor XIIa inhibitor for HAE prophylaxis, positioning KalVista to address the full spectrum of HAE disease management. Factor XIIa inhibitor program is developed to address other therapeutic areas, including inflammation and thrombosis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
KALVISTA PHARMACEUTICALS INC - INITIAL DATA INDICATES SEBETRALSTAT PROVIDES PROMPT AND EFFICIENT TREATMENT FOR HAE IN CHILDREN
Study Findings: Interim data from Kalvista Pharmaceuticals indicates that their treatment for HA (Hereditary Angioedema) in children is both safe and effective.
Target Population: The research focuses on the early treatment of HA in pediatric patients, highlighting the importance of addressing this condition in children.
See More
KalVista Reports Interim Results of EKTERLY Clinical Trial
- Clinical Trial Progress: KalVista Pharmaceuticals announced interim results from its KONFIDENT-KID trial involving 33 pediatric participants and 172 hereditary angioedema (HAE) attacks, demonstrating effective treatment with the oral dissolving tablet sebetralstat.
- Rapid Treatment Time: The data revealed a median time to treatment initiation of 25 minutes, with 67% of attacks treated within the first hour, indicating sebetralstat's ability to significantly reduce patient wait times and enhance treatment timeliness.
- Symptom Relief Efficacy: For the largest group receiving the 150 mg dose, symptoms began to improve in approximately 1.5 hours and completely resolved within 12 hours, showcasing the drug's rapid effectiveness in alleviating symptoms and boosting confidence among patients and caregivers.
- Future Outlook: KalVista plans to file a new drug application for sebetralstat in the US in Q3 2026, with a launch anticipated in 2027, reflecting the company's strong confidence in the drug's market potential, which could drive future revenue growth.
See More
KALVISTA PHARMACEUTICALS INC: STIFEL INCREASES TARGET PRICE FROM $39 TO $42
- Price Increase Announcement: Stifel has raised the price target for KalVista Pharmaceuticals from $39 to $42.
- Market Implications: This adjustment reflects Stifel's updated outlook on KalVista's performance and potential in the pharmaceutical market.
See More
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
KALVISTA PHARMACEUTICALS INC - INITIAL DATA INDICATES SEBETRALSTAT PROVIDES PROMPT AND EFFICIENT TREATMENT FOR HAE IN CHILDREN
Study Findings: Interim data from Kalvista Pharmaceuticals indicates that their treatment for HA (Hereditary Angioedema) in children is both safe and effective.
Target Population: The research focuses on the early treatment of HA in pediatric patients, highlighting the importance of addressing this condition in children.
See More
KalVista Reports Interim Results of EKTERLY Clinical Trial
- Clinical Trial Progress: KalVista Pharmaceuticals announced interim results from its KONFIDENT-KID trial involving 33 pediatric participants and 172 hereditary angioedema (HAE) attacks, demonstrating effective treatment with the oral dissolving tablet sebetralstat.
- Rapid Treatment Time: The data revealed a median time to treatment initiation of 25 minutes, with 67% of attacks treated within the first hour, indicating sebetralstat's ability to significantly reduce patient wait times and enhance treatment timeliness.
- Symptom Relief Efficacy: For the largest group receiving the 150 mg dose, symptoms began to improve in approximately 1.5 hours and completely resolved within 12 hours, showcasing the drug's rapid effectiveness in alleviating symptoms and boosting confidence among patients and caregivers.
- Future Outlook: KalVista plans to file a new drug application for sebetralstat in the US in Q3 2026, with a launch anticipated in 2027, reflecting the company's strong confidence in the drug's market potential, which could drive future revenue growth.
See More
KALVISTA PHARMACEUTICALS INC: STIFEL INCREASES TARGET PRICE FROM $39 TO $42
- Price Increase Announcement: Stifel has raised the price target for KalVista Pharmaceuticals from $39 to $42.
- Market Implications: This adjustment reflects Stifel's updated outlook on KalVista's performance and potential in the pharmaceutical market.
See More
KalVista Pharmaceuticals Reports 2025 Fiscal Year Performance
- Product Revenue Growth: KalVista Pharmaceuticals achieved $49.1 million in global net product revenue for the eight-month transition period ending December 31, 2025, including $35.4 million in the fourth quarter, indicating steady growth since the launch of EKTERLY, although still in the early stages.
- Rising Operating Expenses: The company's operating expenses surged to $160.2 million, a 43% increase from $117 million in the prior year, primarily driven by the costs associated with commercial launch activities, reflecting the high costs of market promotion.
- Reduced R&D Spending: Research and development expenses were $33.4 million, down 36% from $52.2 million in the prior year, indicating a more cautious spending strategy on new product development in response to current financial pressures.
- Strong Cash Position: As of December 31, 2025, KalVista reported $300 million in cash and investments, believed to be sufficient to fund operations under the current plan, although the company has not yet provided long-term financial guidance.
See More
KalVista Reports $49.1 Million Revenue for EKTERLY® in Eight Months
- Revenue Growth: KalVista reported $49.1 million in global net product revenue for EKTERLY® (sebetralstat) for the eight months ending December 31, 2025, indicating strong market demand and rapid product adoption, which is expected to lay the groundwork for future profitability.
- Patient Initiation Metrics: By February 28, 2026, the company received 1,702 patient start forms in the US, representing nearly 20% of the total US patient population, and activated 724 unique prescribers, demonstrating EKTERLY's swift market penetration and acceptance.
- International Market Expansion: EKTERLY's launch in Japan, facilitated by partner Kaken Pharmaceutical Co., Ltd., has been listed on the National Health Insurance drug reimbursement price list, marking a significant step in the company's global market expansion and enhancing its international competitiveness.
- Significant Clinical Progress: The company completed enrollment in the KONFIDENT-KID Phase 3 trial for pediatric patients aged 2 to 11 a full year ahead of schedule, with plans to file a US new drug application in Q3 2026, further solidifying EKTERLY's position as a foundational therapy for HAE management.
See More
KALVISTA PHARMACEUTICALS INC - ANNOUNCES EPS OF $-2.03 FOR THE EIGHT-MONTH PERIOD ENDING DECEMBER 31, 2025
Company Overview: Kalvista Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases with high unmet medical needs.
Financial Report: The company reported earnings of $2.03 per share for the eight months ending December 31, 2025.
See More
